| Literature DB >> 35153757 |
Lie Yuan1,2,3, Yongqing Cai4, Liang Zhang1,2,3, Sijia Liu1,2,3, Pan Li5, Xiaoli Li1,2,3.
Abstract
Breast cancer is one of the top-ranked malignant carcinomas associated with morbidity and mortality in women worldwide. Chemotherapy is one of the main approaches to breast cancer treatment. Breast cancer initially responds to traditional first- and second-line drugs (aromatase inhibitor, tamoxifen, and carboplatin), but eventually acquires resistance, and certain patients relapse within 5 years. Chemotherapeutic drugs also have obvious toxic effects. In recent years, natural products have been widely used in breast cancer research because of their low side effects, low toxicity, and good efficacy based on their multitarget therapy. Apoptosis, a programmed cell death, occurs as a normal and controlled process that promotes cell growth and death. Inducing apoptosis is an important strategy to control excessive breast cancer cell proliferation. Accumulating evidence has revealed that natural products become increasingly important in breast cancer treatment by suppressing cell apoptosis. In this study, we reviewed current studies on natural product-induced breast cancer cell apoptosis and summarized the proapoptosis mechanisms including mitochondrial, FasL/Fas, PI3K/AKT, reactive oxygen species, and mitogen-activated protein kinase-mediated pathway. We hope that our review can provide direction in the search for candidate drugs derived from natural products to treat breast cancer by promoting cell apoptosis.Entities:
Keywords: apoptosis; breast cancer; mechanism; monomer; natural products
Year: 2022 PMID: 35153757 PMCID: PMC8836889 DOI: 10.3389/fphar.2021.801662
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Proapoptotic effects of monomers from natural products on breast cancer cells.
| Monomers | Chemical structure | Detail mechanisms | Cell model | Refs | |
|---|---|---|---|---|---|
|
| |||||
| Ganoderic acid DM (50 µM) |
| Cleaved PARP, γ-H2AX | CDK2, CDK6, p-Rb, CytoC | MCF-7 |
|
| 18β-Glycyrrhetinic acid (100 µM) |
| CytoC, activated caspase-9, Bax | Bcl-2 | MCF-7 |
|
| Apigenin (10, 20, 40, 80 μM) |
| p53, p21, Bax, p-Cdc2, cleaved caspase-3, cleaved PARP | Bcl-2, cyclin B1, Cdc2 | T47D |
|
| Stevioside (10 µM) |
| Bax, Caspase-9 | Bcl-2 | MCF7 |
|
| Amentoflavone (250 µM) |
| Bax, p53 | Bid | MCF-7 |
|
| Calycosin (25, 50, 100 µM) |
| Bax | Bcl-2 | MCF-7 |
|
| Thymoquinon (with 12.30 ± 0.62 μM in MDA-MB-468 with 18.06 ± 0.71 μM in T-47D) |
| p27, Bax, CytoC, pro–caspase-3, cleaved PARP | Cyclin D1, cyclin E, Bcl-2, BclXL, survivin, p-PDK1, p-PTEN, p-Akt, p-GSK-3β, p-Bad, 4E-BP1, eIF4E, p-S6R, p-p70S6K | MDA-MB-468 T-47D |
|
| Embelin (40, 80 µg/mL) |
| Bax, CytoC, caspase-3, caspase-9 | Bcl-2 | MCF-7 |
|
|
|
| p53, Bad, cleaved caspase-3, cleaved PARP | MCF-7 | MDA-MB-231 |
|
| Oleuropein (100, 200 μM) |
| p53, Bax | Bcl-2 | MCF-7 |
|
| Ursolic acid (20, 40, 80 μmol/L) |
| p16, p27, activated caspase-3, activated caspase-9 | MDA-MB-231 |
| |
| 3β, 6β, 16β-trihydroxylup-20 (29)-ene (TTHL) (0.5, 1.36, 3.70 μg/mL) |
| Cleaved caspase-9, ROS | MCF-7 |
| |
| Dioscin (1, 2, 4, 6,8 μM) |
| Cleaved caspase-3, cleaved PARP | Bcl-2, cIAP-1, Mcl-1 | MDA-MB-231 |
|
| Emodin (10, 40 µM) |
| Cleaved caspase-3, PARP, p53, Bax | Bcl-2 | Bcap-37 ZR-75-30 |
|
| Gaillardin (1, 10, 100 mM) |
| Bax, p53 | Bcl-2 | MCF-7 MDA-MB-468 |
|
| Sesamin (1, 10, 50 μM) |
| Bax, caspase-3, p53 | MCF-7 |
| |
| 20(S)-protopanaxadiol (0–60 ml) |
| Bax, cleaved PARP, p53 | Bcl-2, CytoC, cyclin D1, CDK4 | MCF-7 |
|
| 4-Methylthiobutyl isothiocyanate (2.5, 5, 10, 20 μM) |
| Cleaved caspase-9, cleaved caspase-3 | PARP | MDA-MB-231 MCF-7 |
|
| Paratocarpin E (10, 20, 30, 40 μM) |
| Cleaved caspase-8, cleaved caspase-9, Bax, CytoC | Bcl-2 | MCF-7 |
|
| Arecoline (10, 30, 50, 100, 300, 500 μmol/L) |
| p53, Bax | Bcl-2 | MCF-7 |
|
| Amygdalin (10, 20, 40 mg/mL) |
| Bax, activated caspase-3, cleaved PARP, p-p38 | Bcl-2 | Hs578T |
|
| Osthole (25, 50, 100 μmol/L) |
| Bax, p53, p21, CytoC | Bcl-2 | MCF-7 |
|
| Cordycepin (50, 100 μM) |
| Cleaved caspase-8, cleaved caspase-9, cleaved caspase-3, Bax | Bcl-2 | MCF-7 MDA-MB-231 |
|
| Violacein (0.45, 4.5 μM) |
| Bax, p53, caspase-3, Fas, FADD | Bcl-2, MDM2 | MCF-7 |
|
| Berberine (5, 10, 20, 40 µg/mL) |
| Cleaved caspase-3, cleaved caspase-9, Bax, CytoC | Bcl-2 | BT549 MDA-MB-231 |
|
| Liriodenine (0.1, 1, 10 µM) |
| p53 | Bcl-2, cyclin D1 | MCF-7 |
|
| Polyphyllin I (8 μM) |
| Cleaved caspase-9, cleaved caspase-3, cleaved PARP | MDA-MB-231 |
| |
| Clematis hederagenin saponin (0.08, 0.4, 2, 10 µg/mL) |
| Caspase-3, caspase-9 | Apaf-1, CytoC | MCF-7 MDA-MB-231 |
|
| Kaempferol (50 μmol/L) |
| Cleaved caspase-9, cleaved caspase-3, p-A TM | MDA-MB-231 cells |
| |
| Diosgenin (5, 10, 20, 40 µM) |
| CytoC, cleaved caspase-9 | Bcl-2 | MCF-7 Hs578T |
|
| Baicalein (50, 100 µM) |
| Bax, CytoC, cleaved caspase-9, cleaved caspase-3 | Bcl-2 | MCF-7 |
|
| Allicin (20, 45 µM) |
| Activated caspase-3, activated caspase-8, activated caspase-9 NOXA, p21, Bak | BclXL | MCF-7 HCC-70 |
|
| Diosmetin (5, 10, 20, 30, 40, 50, 60, 70 μm/L) |
| p53, Bax, caspase-3 | Bcl-2 | MCF-7 |
|
| Arnidiol (60 μM) |
| PARP, cleaved caspase-3 | MDA-MB-231 |
| |
| Catechol (10, 40, 80 μM) |
| p-H2AX, p-ATM, p-ATR, cleaved caspase -9, cleaved caspase-3, Bax | BclXL, Bcl-2 | MDA-MB-231 |
|
| Resveratrol (12.5, 25, 50, 100, 200 μM) |
| Cleaved PARP1, cleaved caspase-3 | PCNA, Bcl-2 | MDA-MB-231 |
|
| Cepharanthine (2 μM) |
| Cleaved caspase-3, cleaved PARP | MDA-MB-231 |
| |
| Dehydrocostuslactone (5, 10, 20, 30, 40, 50, 60, 80, 100 μmol/L) |
| Bax, caspase-3, cleaved caspase-3 | Bcl-2 | SK-BR-3 |
|
|
| |||||
| Icariside II (25, 50, 75 µM) |
| CytoC, cleaved caspase-3, cleaved PARP, cleaved caspase-7, cleaved caspase-8, Fas, FADD, BclXL, Bax, Bim | MCF7 |
| |
| Gambogenic acid (0.4, 0.6, 0.8, 1.0 µg/mL) |
| Fas, cleaved caspase-3, cleaved caspase-8, cleaved caspase-9, Bax | Bcl-2 | MDA-MB-231 |
|
| Genistein (0, 5, 10, 20 μmol/L) |
| FADD, cleaved caspase-8, FasL | MDA-MB-231 |
| |
| α-Mangostin (1, 2, 3, 4 μM) |
| Cleaved PARP, Bax | Fas, Bcl-2, p-Fak | MCF-7 MDA-MB-231 |
|
| Fraxetin (20, 40, 60 µM) |
| Fas, FasL, Bax | Bcl-2 | MCF-7 |
|
| Pulveraven A (50,100 µM) |
| FADD, cleaved caspase-7, cleaved caspase-8, cleaved PARP, Bax | Bcl-2 | MCF-7 |
|
|
| |||||
| 18β-Glycyrrhetinic acid (100 µM) |
| CytoC, activated caspase-9, Bax | Bcl-2 | MCF-7 |
|
| Fangchinoline (5, 10, 20 μmol/L) |
| p-PI3K, p-Akt, p-mTOR | MDA-MB-231 |
| |
| Cucurbitacin E (100–200 nM) |
| Cleaved caspase-3, cleaved PARP | Cyclin D1, survivin, Mcl-1, XIAP, Bcl-2, p-STAT3, p-ERK, p-AKT | MDA-MB-468 |
|
| Lycopene (100 μM) |
| Cleaved PARP, p21, Bax | p-Akt, p-mTOR, cyclin D1 | MDA-MB-468 |
|
| Piperlongumine (5, 10, 15, 20, 25 μM) |
| Bax, CytoC | p-Akt, p70S6K1, 4EBP1, cyclin D1, Bcl-2, p53 | MDA-MB-231 |
|
|
|
| p-PI3K, p-Akt | MDA-MB-231 MCF-7 |
| |
| Genistein (0, 20, 40, 80 μM) |
| Bax | p-Akt, Bcl-2 | MCF-7 |
|
| Isorhamnetin (10 μM) |
| Bax, cleaved caspase-3 | p-Akt, p-mTOR, p-MEK1/2, p-ERK1/2, Bcl-2, BclXL | MCF7 MDA-MB-468 |
|
| Calycosin (80 μM) |
| p-Akt, HOTAIR | MCF-7 |
| |
| Ramentaceone (5, 10, 15 μM) |
| Bax, Bak, cleaved caspase-3, cleaved PARP | PI3K p85, p-PI3K, p-Akt (Ser473), Bcl-2 | BT47 SKBR3 MCF-7 MDA-MB-231 |
|
| Ginsenoside Rg3 (100 ng/mL) |
| p-Akt, MGBA | MDA-MB-231 |
| |
| α-Mangostin (15, 30 μM) |
| Cleaved caspase-3, cleaved caspase-9 | Bcl-2, Mcl-1 | T47D |
|
| Cepharanthine (with 10 µM in MCF-7 cells, with 6 µM in MDA-MB-231 cells) |
| Bax, Bad, cleaved caspase-3, cleaved caspase-9 | Bcl-2 | MCF-7 MDA-MB-231 |
|
| Baicalein (10, 20, 40 µM) |
| IκB | p-Akt, p-mTOR, NF-κB, p-IκB | MCF-7 MDA-MB-231 |
|
| Fisetin (20μM, 40μM, 80 μM) |
| Bax, caspase-3, caspase-8, caspase-9 | p-PI3K, p-Akt, p-mTOR, p-P70 | 4T1 |
|
| Stachydrine hydrochloride (5, 20, 50, 100, 200 µM) |
| Cleaved caspase-3 | Bcl-2, p-Akt, p-ERK | MCF-7 T47D |
|
| Paris saponins (XA2) (1.25, 2.5, 5 µM) |
| p-Akt, p-mTOR, p-P70S6K | MCF-7 MDA-MB-231 |
| |
| Ginsenoside Rg5 (10, 20 mg/kg) |
| Ras, cleaved caspase-8, cleaved caspase-9, Bax, CytoC | Bcl-2 | MCF-7 |
|
| 20(S)-protopanaxadiol (15, 30, 60 µM) |
| p-PTEN, p53 | p-Akt (Thr308), p-Akt (Ser473), p-mTOR (Ser2448), p-FoxO1 (Ser256), p-MDM2 (Ser166), p-NF-κB, p65 (Ser536), p-GSK-3β (Ser9), p27kip1, CytoC | MCF-7 |
|
| Galangin (20, 40, 80, 160 μmol/L) |
| Bax, cleaved caspase-9, cleaved caspase-8, cleaved caspase-3, cleaved Bid, Bad, p21, p27, p53 | Bcl-2, p-PI3K, p-Akt, cyclin D3, cyclin B1, CDK1, CDK2, CDK4 | MCF-7 |
|
| Tetramethylpyrazine (800, 1,600, 3,200 µM) |
| Cleaved caspase-3 | p-Akt | MDA-MB-231 |
|
| Daucosterol linoleate (25, 50, 100 mg/mL) |
| Cleaved caspase-3, cleaved caspase-7, cleaved caspase-8, cleaved caspase-9, cleaved PARP-1, Bax, Bad | BclXL, Bcl-2, XIAP | MCF-7 |
|
| Cannabidiol (1–7 µM) |
| PPARγ | mTOR, cyclin D1 | MDA-MB-231 T-47D |
|
| Crambescidin 800 (0.01, 0.1, 0.5, 1, 5, 10,15, 20 µM) |
| p21 | Cyclin D1, CDK4, CDK6 | T11 SUM159PT |
|
| Eupatorin (5 μg/mL) |
| Bak1, HIF1A, Bax, Bad, CytoC, SMAC/Diablo, activated caspase-9, activated caspase-8, Rb-Raf-1, GSK-3β | Akt (pan), p-PDK1 | MDA-MB-231 |
|
| Kaempferol (25, 50, 100 μmol/L) |
| p-PI3K, p-AKT, p-GSK-3β | SUM190 |
| |
| Curcumin (10, 30 µM) |
| p21, Bax, cleaved caspase-3 | CDC25, CDC2, Bcl-2 | T47D MCF-7 |
|
| Ginsenoside Rk1 (40, 80, 120 µM) |
| Bax, CytoC, cleaved caspase-3, cleaved caspase-8, cleaved caspase-9 | Bcl-2 | MDA-MB-231 |
|
| Parthenolide (5, 10 μmol/L) |
| Caspase-3 | Bcl-2 | MDA-MB-231 MCF-7 |
|
| Flavopereirine (5, 10, 15 μM) |
| Cyclin D1, cyclin E1, p21, 27, activated caspase-3, activated caspase-9, cleaved PARP, p-ERK1/2, p38 | Cyclin A2, CDK-2, BclxL, cleaved caspase-8 | MDA-MB-231 |
|
| Avicularin (6.25, 12.5, 25, 50, 100 μmol/L) |
| PI3K, p-PI3K, AKT, p-Akt, Bcl-2, BclXL, CDK2 | MDA-MB-231 |
| |
| Magnoflorine (1.25, 2.5, 5 μM) and Doxorubicin (0.1, 0.25, 0.5, 1 μM) |
| p21, p53, cleaved caspase-9, cleaved caspase-3, Beclin-1, LC3-I | CDK1, CDK2, cyclin B1, Bcl-2, p62 | MCF-7 MDA-MB-231 |
|
| Erianin (40, 80, 160 nM) |
| p21, p27, PARP, Bax, caspase-3, caspase-9 | CDK1, cyclin B1, p-PI3K, p-Akt | MDA-MB-231 EFM-192A cell |
|
|
| |||||
| Formononetin (25, 50, 100 µM) |
| Bax, Ras, Raf, p-p38 | Bcl-2 | MCF-7 |
|
| Genipin (0.05, 0.1, 1 mM) |
| Bax, activated caspase-3, p38, p-JNK | Bcl-2 | MDA-MB-231 |
|
| Tetramethylpyrazine (0.25, 0.50, 1.00, 1.50, 2.00 mg/mL) |
| p-p38, p-JNK | p-ERK | MCF7 |
|
| Deoxypodophyllotoxin (101–104 ng/mL) |
| Cleaved caspase-3, ERK1/2, IkB-α | p-ERK | MB231 |
|
| Emodin (20, 40, 80 μmol/mL) |
| AP-1 | MCF-7 |
| |
| Quercetin (40 μM) |
| p21 | Cyclin D1, Twist, p-p38 | MCF-7 |
|
| Quercetin (20 μM) |
| FasL, GADD45, p53, p21, p-JNK, translocation of Foxo3a | MDA-MB-231 |
| |
| Isocryptotanshinone (2.5, 5, 10 μM) |
| Bsx, Bak, cleaved PARP, cleaved caspase-3, cleaved caspase-9, p-JNK, p-ERK, p-p38 | Bcl-2, BclXL | MCF-7 |
|
| Gallic acid (5, 25, 50 µM) |
| p21Cip1, p27Kip1, activated caspase-9, activated caspase-3 | Cyclin D1/CDK4, cyclin E/CDK2 | MDA-MB-231 |
|
| Sophoraflavanone G (5, 10, 15, 20, 30 µM) |
| Cleaved caspase-8, cleaved caspase-3, cleaved caspase-9 | Bcl-2, BclXL | MDA-MB-231 |
|
| Cardamonin (CD) (20 µM) |
| Foxo3a, p27, p21, Bim, p-JNK, cleaved caspase-3 | Cyclin D1 | MDA-MB 231 MCF-7 |
|
| Silymarin (100, 200 µg/mL) |
| Bax, cleaved PARP, cleaved caspase-9, p-JNK | Bcl-2, p-p38, p-ERK1/2 | MDA-MB-231 MCF-7 |
|
|
| |||||
| Oridonin (20 µM) |
| Bax, cleaved PARP, Fas, PPARγ | Bcl-2, caspase-8, NF-κB (p65), IKKα, IKKβ, p-mTOR | MDA-MB-231 MCF-7 |
|
| Delphintin (10, 20, 40, 80, 160 μmol/L) |
| IκBα, IKKα, IKKβ, PKCα | p-NF-κB/p65, p-IκBα, p-IKKα/β, p-PKCα | MDA-MB-453 BT-474 |
|
| Chrysophanol (5, 10, 20 µM) |
| p27, cleaved caspase-3, cleaved PARP | Cyclin D1, cyclin E, Bcl-2, p65, IκB | MCF-7 MDA-MB-231 |
|
| Capsaicin (100, 150 μmol/L) |
| Bax, cleaved caspase-3 | FBI-1, Ki-67, Bcl-2, survivin | MCF-7 MDA-MB-231 |
|
|
| |||||
| Vernodalin (3.125, 6.25, 12.5 µg/mL) |
| CytoC, cleaved PARP, caspase-3, cleaved caspase-7, cleaved caspase-9 | Bcl-2, BclxL, MMP | MCF-7 MDA-MB-231 |
|
| Ziyuglycoside II (2.5, 10, 40 µM) |
| p21/WAF1, p-Cdc25C, p-Cdc2 | Cdc25C, Cdc2, cyclin A, cyclin B1 | MDA-MB-231 MCF-7 |
|
| Fucoidan (0.2–1 mg/mL) |
| Caspase-8, CytoC, Bax | Cyclin D1, CDK-4, Bcl-2 | MCF-7 |
|
| Berberine (50 μM) |
| Bax, ROS, p-JNK, CytoC, AIF, activated caspase-3 | Bcl-2 | MDA-MB-231 MCF-7 |
|
| Geraniin (5, 10, 25 μM) |
| Cleaved PARP, cleaved caspase-3 | Bcl-2, p-ERK1/2, p-Akt, p-p38 | MCF-7 |
|
| Hyperoside (25, 50, 100 µM) |
| Bax, cleaved caspase-3 | Bcl-2, XIAP | MCF-7 cells 4T1 cells |
|
| Crocin (0.5–6 mM) |
| Foxo3a, Bim, PTEN, activated caspase-3, BAX | Bcl-2 | MCF-7 MDA-MB-231 |
|
| Tetrandrine (51 μM) |
| Activated caspase-8, activated caspase-9, activated caspase-3 | MDA-MB-231 |
| |
| (−)-Epicatechin (350 μM) |
| Bad, Bax | MCF-7 MDA-MB-231 |
| |
| Formononetin (8, 16, 32, 64, 128 μmol/L) |
| Bax, cleaved caspase-3 | Bcl-2 | MCF-7 |
|
|
| |||||
| Apigenin (0, 20, 40, 60 μM) |
| Cleaved caspase-8, cleaved caspase-3, cleaved PARP | p-JAK2, p-STAT3 | MDA-MB-453 (HER2-overexpressing) |
|
| Berberine (10, 20, 40 μg/mL) |
| Bax, cleaved PARP, cleaved caspase-3 | p-JAK2, p-STAT3, Bcl-2 | MCF-7 |
|
| 7β-(3-Ethyl- |
| Cleaved caspase-3, cleaved caspase-8, cleaved PARP | p-STAT3 (Tyr705), p-JAK1, p-JAK2, p-Src, Bcl-2, COX-2, cyclin D1 | MDA-MB-231 |
|
| Curcumol (0, 12.5, 25, 50, 100 μg/mL) |
| p-JAK2, p-STAT3 | MCF-7 |
| |
| Saikosaponin D (0, 5, 10, 20 μmol/L) |
| JAK2, STAT3, Ki-67 | MCF-7 |
| |
|
| |||||
| Fucoxanthin (10, 20, 40 μmol/L) |
| Bax, activated caspase-4, activated caspase-7, activated caspase-9, CytoC | Bcl-2 | MCF-7 |
|
| Oleandrin (with 14.5 nM in MCF-7, with 24.62 nM in MDA-MB-231) |
| Bax, Bim, IF2α, ATF4, CHOP, p-PERK, p-eIF2α | Bcl-2 | MCF-7 MDA-MB-231 |
|
| Salviaflaside (0.1, 1, 10 μmol/L) |
| GRP78, ATF4, CHOP, p-PERK, p-eIF2α, cleaved caspase-3 | Bcl-2/Bax | MDA-MB-231 |
|
|
| |||||
| Curcumin (30 µmol/mL) |
| pERK1/2, pEGFR | MDA-MB-231 |
| |
| Ursolic acid (10, 20, 30 µmol/L) |
| FOXM1, cyclin D1, CDK4 | MCF-7 |
| |
| Triptolide (10, 25, 50 nM) |
| β-Catenin | MDA-MB-231 BT-474 |
| |
| Calycosin (10, 50, 100 μL) |
| p53, Cleaved caspase-3 | SIRT1 | MCF-7 |
|
| Gambogic acid lysinate (0.25, 0.50, 1.00, 2.00, 4.00, 8.00 μmol/L) |
| Cleaved caspase-3 | SIRT1 | MCF-7 |
|
| Icariin (10, 25, 50, 75 µM) |
| Caspase-3, PARP, p62 | CDK2, CDK4, cyclin D1, Bcl-2, LC3-1, LC3-II, AGT5, Beclin-1 | MCF-7/TAM |
|
| Ellagic acid (1–10 μM) |
| CDK6 | MCF-7 MDA-MB-231 |
| |
| Flavonoid calycopterin (150 μM) |
| Bax, caspase-3, caspase-8 | Bcl-2 | MDA-MB-231 |
|
| Quercetin (40, 80, 160 μmol/L) |
| GAS5, Bax, caspase-3 | Notch1, Jagged1, Hes1, Bcl-2 | MCF-7 |
|
| Rhamnetin (15,FPHAR_fphar-2021-801662_gs_fx121 20, 25 µM) |
| Activated caspase-3, activated caspase-9, (miR-)34a, p53 | Notch1 | MCF-7 |
|
| Shikonin (0.625, 1.25, 2.5 µM) |
| cIAP1, cIAP2, RIP1 | MDA-MB-231 |
| |
| Cordycepin (40, 80, 120 µM) |
| PUMA, CytoC, Fas, DR4/5, cleaved caspase-3 | Bcl-2, XIAP, PDGFR-α | MDA-MB-231 MDA-MB-468 MCF-7 |
|
FIGURE 1Natural products induced apoptosis through mitochondrial pathway. (1) Kaempferol, (2) berberine, (3) Clematis hederagenin saponin, (4) ursolic acid, (5) ganoderic acid DM, (6) stevioside, (7) Calycosin, (8) thymoquinon, (9) amygdalin, (10) catechol, (11) apigenin, (12) oleuropein, (13) diosgenin, (14) embelin, (15) dioscin, (16) violacein.
FIGURE 2Natural products induced apoptosis through FasL-Fas pathway. (1) Fraxetin, (2) gambogenic acid, (3) icariside II, (4) pulveraven A.
FIGURE 3Natural products induced apoptosis through PI3K/AKT pathway. (1) cepharanthine, (2) piperlongumine, (3) fangchinoline, (4) lycopene, (5) genistein, (6) ramentaceone, (7) baicalein, (8) 18β-glycyrrhetinic acid, (9) tetramethylpyrazine, (10) cucurbitacin e, (11) ramentaceone, (12) baicalein, (13) daucosterol linoleate, (14) kaempferol, (15) flavopereirine.
FIGURE 4Natural products induced apoptosis through MAPK pathway. (1) Tetramethylpyrazine, (2) emodin, (3) quercetin, (4) Deoxypodophyllotoxin.
FIGURE 5Natural products induced apoptosis through ROS pathway. (1) Crocin, (2) geraniin, (3) ziyuglycoside II, (4) hyperoside.
Extracts from natural products induced apoptosis in breast cancer.
| Extracts | Compositions | Detail mechanisms | Cell model | Refs | |
|---|---|---|---|---|---|
| Upregulation | Downregulation | ||||
|
| Phalerin | PTEN, p21, Bax, Bad, PUMA, activated caspase-9, cleaved PARP | p-Akt, BclxL | MDA-MB-231 |
|
|
| Protocatechuic acid, p-hydroxybenzoic acid, cinnamic acid | p53, p21, cleaved PARP | Bcl-2, XIAP | MCF-7 |
|
|
| Verbascosaponin, crokoelziside, isolated from these fractions | Caspase-3 mRNA, caspase-9 mRNA | MCF-7 |
| |
| Ethyl acetate extracts of seeds of | Hexanoic acid, 2-heptenal, 2,4-nonadiena, 1,1′-carbonyldiimidazole, 1-oxaspiro [4,4]nonan-4-one, 5,5-dimethyl-cyclohex-3-en-1-ol, (E,E)-7,11,15, trimethyl-3-methylene-1,6,10,14-tetraene, l-(+), ascorbic acid 2,6-dihexadecanoate, 6-octadecenoic acid, octadecanoic acid, palmitin, octadecanoic acid 2,3-dihydroxypropyl ester | p53, Bax, Bak, Bad, cyclin B1, cyclin E, CDC2 | NF-κB, Bcl-2, Mcl-1, p-ERK, p-p38, p-JNK, p-Akt | MDA-MB-231 |
|
|
| Lycopene, β-carotene | Bax, activated caspase-6, activated caspase-8, activated caspase-9 | MCF-7 |
| |
| Extracts from chickpea | Ononin isoflavone, biochanin A-7-O-β-D-glucoside isoflavone, formononetin isoflavone, biochanin A isoflavone | Bax, caspase-7, caspase-9, p53, p21 | Bcl-2 MCF-7 | SKBr3 |
|
|
| Katonic acid, betulinic acid, koetjapic acid | JNK1 | ERK1, Bcl-2 | MDA-MB-231 |
|
| Green tea polyphenols (200, 300, 400 µg/mL) | Catechins | ROS, cleaved caspase-3, cleaved caspase-9 | MCF-7 |
| |
| Fruit peel polyphenolic extracts flavine (F7) (150 µg/mL) | Myricetin, quercetin, kaempferol, rutin, isorhamnetine, catechin, epicatechin, malvidin-3-glucoside, caffeic acid, chrysin, galangin, apigenin, fisetin, luteolin, morin, anthocyanidins, stilbene resveratrol | Bax, cleaved PARP, activated caspase-7 | Bcl-2 | MCF-7 |
|
| Flavonoid compounds from | IH: isorhamnetin, GN: genkwanin, and Aca: acacetin | p53, cleaved caspase-3, LC3-II, ATG5 | p-Cdc2, cyclin B1, Bcl-2, BclxL, PARP1, p62, PI3Kγ-p110, p-PI3K, p-Akt, p-mTOR, p-p70S6K, p-ULK | MDA-MB-231 |
|
|
| Antcin K, antcin C, antcin B, methyl, antcinate B, eburi-coic acid, dehydroeburicoic acid | miR-21-5p, miR-26-5p, miR-30-5p | Skp2 | MCF-7 |
|
| Hexane fraction from | Alantolactone, isoalantolactone, igalan, dugesialactone, alloantolactone | p-JNK, activated caspase-3, cleaved PARP | Cyclin D1, CytoC, Bcl-2, p-ERK | MDA-MB-231 |
|
|
| Ricinine, p-coumaric acid, epigallocatechin, ricinoleic acid | Bax, CytoC, caspase-7, cleaved PARP | Bcl-2 | MDA-MB-231 MCF-7 |
|
|
| Betulin | Cleaved caspase-9, cleaved caspase-3, cleaved PARP | MMP9, p-Akt, cyclin A/E, Bcl-2 | MDA-MB-231 |
|
| Extracts of | Gallic acid | p53, p21, cleaved caspase-3, caspase-9, PARP, Bax | Bcl-2 | MCF-7 |
|
|
| Vitexicarpin | Caspase-8, caspase-9, caspases-3/7, Bax | Bcl-2 | T-47D |
|
| Extracts from Ajwa dates pulp (15, 20 mg/mL) | Maltose, catechin, myricetin, quercetin, β-sitosterol, digalacturonic acid, chlorogenic acid, β-carotene | p53, Bax, cleaved caspase-3 | Bcl-2, p-Akt, p-mTOR | MDA-MB-231 |
|